Browse articles from EyeWorld.org related to dry eye. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
Cornea Editor Clara Chan, MD, talks about her experience incorporating new techniques and technologies into her practice and previews the articles in the section.
Scleral lenses are an option that many physicians use to help patients suffering from more severe and advanced cases of dry eye disease. Two ophthalmologists discussed the options and how these fit into the treatment of dry eye.
➤ FDA approves image and data management/analysis platform ➤ Results from pivotal Phase 3 trial for new Demodex treatment ➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients ➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate ➤ Phase 3 results for investigational geographic atrophy therapy ➤ New coalition supports sustainability in ophthalmology ➤ ASCRS news and events
➤ Phase 3 clinical trials complete for ‘superpotent’ corticosteroid ➤ New rapid, quantitative MMP-9 tear test ➤ First pediatric patient dosed with experimental gene-editing therapy for Leber congenital amaurosis ➤ Study: Comparison of NCX 470 to latanoprost for glaucoma ➤ Collaborations for inherited retinal diseases ➤ ASCRS news and events
Restasis (cyclosporine ophthalmic emulsion) was developed by Allergan and approved by the U.S. FDA in 2003. Now, after nearly 2 decades since its approval as a brand name drug indicated for symptoms of dry eye, a generic version of Restasis has been approved. It was a “long time coming,” according to Henry Perry, MD.
➤ Topline data from Phase 3 trial of presbyopia-correcting drop ➤ FDA gives 510(K) approval to updated neuromodulation therapy for increased tear production ➤ Enrollment complete for Phase 3 trial of reproxalap ➤ DME trial to focus on underrepresented patient populations ➤ BLA submitted to FDA for wet AMD therapy ➤ Companies collaborate to further develop gene therapy for retinal disease ➤ ASCRS news and events
➤ Launch of Phase 3 clinical trial for presbyopia drop candidate ➤ Topline results for investigational dry eye therapy ➤ Positive findings for photobiomodulation dry AMD treatment ➤ Enrollment completed for investigational oral diabetic retinopathy therapy ➤ Longer-term data from Phase 3 studies evaluating geographic atrophy therapy released ➤ Orphan drug designation granted to investigational retinitis pigmentosa treatment ➤ ASCRS news and events
➤ Results from pivotal amblyopia trial ➤ Phase 2 clinical program for third-generation keratoconus treatment ➤ Study compares tolerability of standard drop vs. novel drug delivery device ➤ Phase 3 clinical studies for investigational presbyopia drop complete ➤ Orphan drug designation granted for fungal keratitis treatment ➤ Full rights regained for investigational dry AMD therapy ➤ ASCRS news and events
➤ FDA approves first drug-eluting contact lens ➤ FDA accepts 510(k) submission for new femto-phaco device ➤ Phase 2 study begins to evaluate an immunomodulatory agent for dry eye ➤ Licensing agreement for optic nerve-protective therapy ➤ Phase 3 study to evaluate protein replacement solution for dry eye ➤ Study: Impact of age on SMILE outcomes ➤ ASCRS news and events
EyeWorld Cornea Editor Clara Chan, MD, discusses “one of her most dramatic cases” involving ocular complications associated with rosacea, previews the content in the Cornea section of this issue, and shares excitement for the ASCRS Annual Meeting.